. 2022 Dec 8;45(1):29–43. doi: 10.1007/s11357-022-00705-1

Table 4.

Adverse event (AE) of the placebo and three NMN-treated groups

	Placebo, n = 20	300 mg NMN, n = 20
Total AEs	6 (67%)^a	3 (33%)^b
Serious AEs	0	0
Dropout due to AEs	0	0
AEs due to supplementation	0	0

^aSymptoms (no. of occurrences): rashes on skin (1), tingling and numbness in all extremities (1), weakness of right upper extremity (1), irrelevant talk (1), mouth ulcer (1), and fever (1). Weakness of the right upper extremity and irrelevant talk happened on the same participant

^bSymptoms (no. of occurrences): hyperacidity (1), skin problem (1), and mouth ulcer (1). Skin problem and mouth ulcer occurred on the same participant